Liftstream is an executive search recruitment company in the life sciences sector
Companies to partner executive search firms which have elevated their D&I expertise, and explicitly request increased candidate diversity.
The UK has been seriously tackling the issue of diversity in the senior ranks of British business. The Davies Review, led by the charismatic but challenging Lord Mervyn Davies, pushed UK boards to get 25% of women on the boards of FTSE 100 companies. This triggered concerted action on the part of the nominated companies because they would be publicly measured, and reported.
Voyager Therapeutics, a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced the appointment of Jane Pritchett Henderson as senior vice president and chief financial officer effective January 1, 2017. Ms. Henderson brings more than 28 years of life sciences industry and banking experience and leadership to her new role.
Two months ago, Liftstream had the privilege of holding our 2nd annual diversity conference in Boston with our partner Biogen. The event, as you perhaps know by now, bought together some great leaders from across life sciences, investment and academia to address the challenges associated with diversifying the talent in the boardroom. We looked predominately at the issue through the lens of gender, but with a broader consideration of all types of diversity, including those less apparent to us, such as cognitive diversity.
Immatics Biotechnologies, a biopharmaceutical company focused on cancer immunotherapy, has appointed Katina Dorton as CFO. “Dorton’s experience working with innovative life sciences companies and strong track record leading corporate transactions and managing financial operations makes her an excellent addition to the Immatics senior management team,” commented Immatics Chairman Peter Chambré.
Aegerion Pharmaceuticals, a biopharmaceutical company dedicated to the development and commercialisation of innovative therapies for patients with debilitating rare diseases, has appointed Mary Szela as CEO and a member of board of directors. Szela replaces interim CEO Sandford Smith who took over after the resignation of former CEO Marc Beer in July 2015. After stepping down as Interim CEO, Smith was appointed chairman of the board of directors, allowing him to continue to work closely with the management team to maintain the momentum on key company initiatives.